|
Sunday October 4, 2009, 1830-1930
Opening Keynote Address: The Role of New Analytical Technologies in Driving the Future of TDM and CT
Monday October 5, 2009, 0800-0900
Plenary P1: Better Biomarkers of Acute and Chronic Allograft Rejection
Tuesday October 6, 2009, 0800-0900
Plenary P2: Neonatal Clinical Pharmacology: Linking Ontogeny, Genetics and TDM in the Most Vulnerable Patients
Wednesday October 7, 2009, 0800-0900
Plenary P3: Understanding the Regulation of Drug Transport in Disease States and its Impact on Drug Response and Kinetics
Thursday October 8, 2009, 0800-0900
Plenary P4: Hot Topics in Drugs of Abuse
Thursday October 8, 2009, 1600-1700
Closing Keynote Address: TDM-CT in the Era of Personalized Medicine - The Future is Now (again)
| SUNDAY OCTOBER 4, 2009, 1830-1930, Opening Keynote |
| |
Opening Keynote Address: The Role of New Analytical Technologies in Driving the Future of TDM and CT
Sunday, 1830-1930
|
Hans H. Maurer, Head, Department of Experimental and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, Saarland University, Homburg/Saar, Germany |
| |
|
|
The Opening Keynote Address will start with a short summary of the current status of analytical tools in TDM and CT. Then trends will be discussed in new technologies, new analytical targets and new data interpretation with probable impact on TDM and CT practice.
Objectives:
- To explore the principles and applications of new analytical technologies in TDM and CT;
- To discuss their pros and cons;
- To assess their usefulness in future science and practice of TDM and CT.
Click here: Hans Maurer biography
 Professor Dr. Dr. h.c. Hans H. Maurer
Hans H. Maurer is full Professor of Pharmacology & Toxicology at the Faculty of Medicine and at the Faculty of Pharmacy, University of Saarland, since 1992. He is head of the Department of Experimental and Clinical Toxicology. His main two areas of research are analytical toxicology (GC-MS, LC-MS of drugs, poisons and their metabolites) and in-vitro and in-vivo metabolism (phase I and phase II, isoenzyme identification, pharmacogenomics). He has published extensively in both areas (besides original papers, reviews and proceedings, handbooks and computer databanks on GC-MS). He is editorial board member of the Journal of Chromatography B, Therapeutic Drug Monitoring, Analytical and Bioanalytical Chemistry, Current Pharmaceutical Analysis, Current Drug Metabolism, Drug Metabolism Letters, Forensic Toxicology, Annales Pharmaceutiques Françaises, SUCHT - German Journal of Addiction Research and Practice He was guest editor of special issues of Journal of Chromatography B (1998), Therapeutic Drug Monitoring (2002 and 2004) and Analytical and Bioanalytical Chemistry (2007).
In his career, Dr. Maurer received several scientific awards, among which the Young Investigator Award of the Medical Faculty presented in Homburg 1983, the Irving Sunshine Award for Outstanding Contributions to Clinical Toxicology of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDM-CT) presented in Vancouver 1997, "Membre d'Honneur" de la Société Française de Toxicologie Analytique (SFTA) presented in Dinard 2003, and finally the Alan Curry Lifetime Achievement Award of TIAFT for Outstanding Contributions to Forensic Toxicology presented in Melbourne 2003. In 2007, he received the Doctor honoris causa (honorary) degree of the University of Ghent in Belgium for his outstanding scientific achievements. Besides his membership in several national and international scientific societies, Dr. Maurer is President of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDM-CT, 2007-2009) and is TIAFT executive board member (2005-2011), treasurer of the Society of Toxicological and Forensic Chemistry (GTFCh, since 1987), chairman of the GTFCh Committee "Clinical Toxicology", since 1997, and finally chapter president of Saarland of the German Pharmaceutical Society (DPhG, 2004-2006).
-------------------------------------------
Go to top |
|
| MONDAY OCTOBER 5, 2009, 0800-0900, Plenary P1 |
| |
Plenary P1: Better Biomarkers of Acute and Chronic Allograft Rejection
Monday, 0800-0900
|
Paul A. Keown, MD, DSc, MBA, FACP, FASN, FRCP, FRCPC, FRCPath, FRSC, FIBiol, Professor of Medicine, Head of Nephrology, Director of Immunology, Chair, Regional Renal Program, University of British Columbia and Vancouver Coastal Health Authority, Vancouver, British Columbia, Canada
|
| |
|
|
Click here: Paul Keown biography
 Paul A. Keown, MD, DSc, MBA, FACP, FASN, FRCP, FRCPC, FRCPath, FRSC, FIBiol
Dr. Paul A. Keown is Professor of Medicine, Director of Immunology and Head of the Division of Nephrology at the University of British Columbia, with appointments in Medicine, Pathology and Laboratory Medicine. Dr. Keown graduated in Medicine from the University of Manchester, and pursued postgraduate training in England, France, and Canada. He holds research Doctorates in both Medicine and in Science from the University of Manchester, and an MBA from Simon Fraser University in British Columbia. Dr. Keown's research focuses particularly on the immune response in transplantation and autoimmune disease, and ranges from molecular genetics to healthcare economics. He is past Executive Director of the British Columbia Transplant Society, past president of the Canadian Transplant Society, a member of Council and Executive Committee of the Transplantation Society, and a member of numerous national and international scientific societies and professional organizations. He was elected a Fellow of: the Royal College of Physicians of Canada in 1977, the Royal College of Physicians of London in 1987, the American College of Physicians in 1994, the American Society of Nephrology and American Society of Angiology in 2008, and the Royal College of Pathologies and Royal Society of Chemistry in 2009. Dr. Keown is the founder and C.E.O. of Syreon Corporation, a global research corporation specializing in the use of advanced information technologies for health sciences research.
-------------------------------------------
Go to top |
|
| |
|
| TUESDAY OCTOBER 6, 2009, 0800-0900, Plenary P2 |
| |
Plenary P2: Neonatal Clinical Pharmacology: Linking Ontogeny, Genetics and TDM in the Most Vulnerable Patients
Tuesday, 0800-0900
|
John N. van den Anker, MD, PhD, FCP, FAAP, Evan and Cindy Jones Chair in Pediatric Clinical Pharmacology, Vice Chair of Pediatrics for Experimental Therapeutics, Children's National Medical Center, Professor of Pediatrics, Pharmacology & Physiology, GWU School of Medicine and Health Sciences, Washington, D.C., USA
|
| |
|
|
Neonatal clinical pharmacology deals with the first frontier of therapeutics for children: the very sick and vulnerable preterm or full-term neonate. For safe and effective pharmacotherapy in these infants it is imperative to link developmental changes in absorption, distribution, metabolism and elimination of frequently used medicines with the inherited capacity to handle these medicines appropriately. In addition, this session will address the potential usefulness or uselessness of therapeutic drug monitoring of the most frequently used medicines in this fragile population.
Click here: John van den Anker biography
John N. van den Anker, MD, PhD, FCP, FAAP
Dr. John van den Anker received his Medical Degree in 1983 from Erasmus University, Rotterdam, the Netherlands and was a resident in Pediatrics (1984-1988) and a fellow in Neonatal Medicine (1989-1991) at Sophia Children’s Hospital in Rotterdam, the Netherlands. In 1995 he received his PhD in Pharmacology and in 1997 he became Director of Neonatology and Professor of Pediatrics and Neonatology at Erasmus University.
Currently he is the Vice Chairman of Pediatrics for Experimental Therapeutics, and Chief of Pediatric Clinical Pharmacology at Children’s National Medical Center in Washington, DC, USA and is appointed as Professor of Pediatrics, Pharmacology & Physiology at George Washington University School of Medicine and Health Sciences. Since 2005 he holds the Evan and Cindy Jones Chair in Pediatric Clinical Pharmacology at Children’s National Medical Center.
He has been granted several major awards from the National Institute of Health (NIH) and leads one of the 13 Pediatric Pharmacology Research Units in the USA.
He has published over 150 peer reviewed papers in the field of neonatal and pediatric clinical pharmacology and serves on the Editorial Board of several Clinical Pharmacology journals.
-------------------------------------------
Go to top |
|
| |
|
| WEDNESDAY OCTOBER 7, 2009, 0800-0900, Plenary P3 |
| |
Plenary P3: Understanding the Regulation of Drug Transport in Disease States and its Impact on Drug Response and Kinetics
Wednesday, 0800-0900
|
Micheline Piquette-Miller, Ph.D., Professor, Faculties of Pharmacy and Medicine, University of Toronto, Toronto, Ontario, Canada |
| |
|
While it is a well established fact that drug disposition is often altered in patient populations, the impact of underlying disease states has been largely neglected as an important source of inter-subject variability. Infectious and inflammatory stimuli results in an immediate and often dramatic alteration in the production of numerous liver-derived proteins. Over the past 30 years, inflammation associated changes in plasma drug concentrations and toxicity have been reported in patients and animal models. Many of these changes were ascribed to altered metabolism and plasma protein binding. Emerging evidence within the last decade has also implicated involvement of drug transporters. Transport proteins play a critical role in the absorption, distribution and clearance for numerous drugs, toxins and their metabolic products and may thus play a role in these changes. Specifically, several drug transporters which are highly expressed in biologically protective barriers of the liver, intestine, blood brain barrier and placenta profoundly impact the passage of xenobiotics across these membranes and thus significantly impact drug activity and toxicity. Studies in animal models have demonstrated significant inflammation-mediated reductions in the expression of many of the ABC drug efflux transporters, organic anion drug uptake transporters and the CYP3A drug metabolizing enzymes in these tissues. These changes are associated with altered drug accumulation and clearance. As drug transporters are involved in the distribution and elimination of a large number of chemically diverse and clinically important drugs, our studies suggest that disease-induced changes in the expression and activity of these proteins likely contribute to intra- and inter-subject variability of drug disposition and response in patients.
Objectives:
At the conclusion of this session the participant will:
- Understand the role of drug transporters in drug distribution and clearance;
- Recognize that the inflammatory response alters the expression of many drug transporters in biologically protective membranes of the liver, intestine, brain and placenta;
- Be aware that inflammation-mediated changes impact drug clearance, tissue accumulation and fetal drug exposure.
Click here: Micheline Piquette-Miller biography
Micheline Piquette-Miller, PhD
Dr. Micheline Piquette-Miller’s research specializes in the area of drug transport and molecular pharmacokinetics. Dr. Piquette-Miller completed a pharmacy degree and PhD in Pharmacokinetics at the University of Alberta and continued post-doctoral training at the University of California in San Francisco. She is currently a Professor at the University of Toronto within the Faculties of Pharmacy and Medicine. Dr. Piquette-Miller has been the recipient of numerous prestigious national and international research awards and has held positions on the executive councils of the American Society of Clinical Pharmacology and Therapeutics, the Canadian Society of Clinical Pharmacology and the Canadian Society of Pharmaceutical Science. She is currently past-president of the Canadian Society of Pharmacology and Therapeutics and is an Associate Editor of Nature’s Clinical Pharmacology and Therapeutics.
-------------------------------------------
Go to top |
|
| |
|
| THURSDAY OCTOBER 8, 2009, 0800-0900, Plenary P4 |
| |
Plenary P4: Hot Topics in Drugs of Abuse
Thursday, 0800-0900
|
Marilyn A. Huestis, Ph.D., Chief, Chemistry and Drug Metabolism, Intramural Research Program, NIDA, NIH Biomedical Research Center, and Adjunct Professor, Toxicology, School of Medicine, University of Maryland Baltimore, Baltimore, Maryland, USA |
|
|
Three of the hot topics in drugs of abuse are how to differentiate new cannabis use from residual urinary cannabinoid excretion in chronic, frequent cannabis users, how to best monitor in utero drug exposure at birth and during gestation, and what role oral fluid testing will play in clinical and forensic toxicology. We have recently revised our models for predicting new cannabis use in occasional users to include the specific interval between urine specimens. This has allowed greater accuracy in predicting new drug use and should provide highly useful data for toxicologists, clinicians, treatment providers and others responsible for interpreting urine cannabinoid drug tests. In addition, for the first time we have developed a model for differentiating new cannabis use from residual urine excretion of cannabinoids in chronic, frequent cannabis users. The model also employs the interval between specimens and provides median and maximum ratios based on over 120,000 comparisons of urine specimens collected from chronic cannabis users during 24 h monitored abstinence. The incidence of prenatal drug exposure is poorly understood due to lack of monitoring of biological specimens, cost and turnaround time for laboratory results, and few controlled pharmacotherapy administration studies or monitoring of illicit drug use during gestation to guide result interpretation. The latest available research on the advantages and disadvantages of testing neonatal and/or maternal urine, hair, meconium, umbilical cord and placenta will be presented. For the first time, we have urine test results available throughout pregnancy to compare to specimens available at birth, giving us an indication of the detection windows for identifying drug use during gestation. Finally, oral fluid drug testing is growing at a rapid pace in clinical and forensic toxicology. The advantages and limitations of this new alternative matrix in workplace drug testing and driving under the influence of drugs investigations will be presented. Problems associated with cannabinoid testing in oral fluid has been one of the limiting factors to its use, but new advances in this area have improved the capability of oral fluid testing to compete with urine drug testing. Oral fluid testing will become commonplace and important in many clinical laboratories in the near future.
Objectives:
At the conclusion of this session the participant will be able to:
- Discuss how to differentiate new cannabis use from residual urinary cannabinoid excretion in chronic, frequent cannabis users;
- Discuss the advantages and limitations of different alternative matrices for monitoring in utero drug exposure at birth and during gestation;
- Discuss oral fluid drug testing for workplace drug testing, drug treatment, emergency toxicology, driving under the influence of drugs and criminal justice programs.
Click here: Marilyn Huestis biography
Marilyn A. Huestis PhD
Marilyn A. Huestis, Ph.D., is a tenured senior investigator and Chief, Chemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, and Adjunct Professor, University of Maryland Baltimore School of Medicine. Her research program seeks to discover mechanisms of action of cannabinoid agonists and antagonists, effects of in utero drug exposure, and to understand the neurobiology and pharmacokinetics of MDMA (Ecstasy). Her section also supports medication development projects including the use of buprenorphine as pharmacotherapy in opioid dependence. Dr. Huestis directed the first clinical Cooperative Research And Development Agreement (CRADA) for the Intramural Research Program that has served as a model for future research endeavors. Dr Huestis has more than 184 peer-reviewed manuscripts, and over 260 abstracts presented at national and international meetings.
Dr. Huestis received a bachelor's degree in biochemistry from Mount Holyoke (cum laude), a master's degree in clinical chemistry from the University of New Mexico, and a doctoral degree in toxicology from the University of Maryland in Baltimore. She has received the American Association for Clinical Chemistry Outstanding Contributions in a Selected Area of Research Award in 2008, the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) Irving Sunshine Award 2007 for excellence in Clinical Toxicology, the American Academy of Forensic Sciences’ Rolla N. Harger Award for lifetime contributions in forensic toxicology in 2005, and the Irving Sunshine Award for “Outstanding Research in Forensic Toxicology” in 1992 for her work on cannabis. She serves on the Transportation Research Board’s Committee on Alcohol and Other Drugs, World Anti-doping Agency’s Prohibited List Committee, and provides consultation for the Office of National Drug Control Policy and Department of Health and Human Services. Dr. Huestis is past president of the Society of Forensic Toxicologists, past Chair of the Toxicology Section of the American Academy of Forensic Sciences, and the first woman president of the International Association of Forensic Toxicologists.
-------------------------------------------
Go to top |
|
| |
|
| THURSDAY OCTOBER 8, 2009, 1600-1700, Closing Keynote |
| |
Closing Keynote Address: TDM-CT in the Era of Personalized Medicine - The Future is Now (again)
Thursday, 1600-1700
|
Alexander A. Vinks, PharmD, PhD, FCP, Professor of Pediatrics and Pharmacology, University of Cincinnati, School of Medicine, Director, Division of Clinical Pharmacology and Pediatric Pharmacology Research Unit, Cincinnati Children's Hospital Medical Center, Cincinnati, USA |
| |
|
The heart of our Society is individualization of therapy, something that is now being ‘re-discovered’ in the era of pharmacogenomic medicine. With Personalized Medicine as one of the ‘hot’ topics in health care, the renewed interest in ‘individualized’ patient care is rapidly gaining support among policymakers and health care professionals as a means for improving patient care and reducing unnecessary health care costs. It is timely to draw the parallel between the many personalized medicine initiatives and the lessons learned from the early days of Therapeutic Drug Monitoring and Clinical Toxicology. At the center of this ongoing debate are clinical laboratories, given that drug concentration measurements remain the cornerstone of many individualized dosing approaches. To make this concept a reality, however, new drug management strategies and web-based algorithms have to be developed and implemented to allow health care providers and patients to optimally benefit from the information generated by pharmacokinetic, pharmacogenetic and biomarker testing.
Aim: To explore the rapidly changing field of personalized patient care and outline how future developments and opportunities may affect how we provide TDM and CT services.
Objectives:
- To explore personalized medicine initiatives and lessons learned from Therapeutic Drug Monitoring and Clinical Toxicology;
- To discuss novel monitoring concepts that complement pharmacogenomic testing;
- To provide a visionary framework of opportunities for our field in this era of renewed focus on individualized patient care.
Click here: Alexander Vinks biography
 Alexander Vinks PharmD, PhD, FCP
Alexander (Sander) Vinks is Professor of Pediatrics and Pharmacology at the University of Cincinnati, Colleges of Medicine and Pharmacy. He is director of the Division of Clinical Pharmacology, principal investigator of the NIH Pediatric Pharmacology Research Unit and Director of the Laboratory of Applied Pharmacokinetics and Therapeutic Drug Management at Cincinnati Children Hospital Medical Center. Dr. Vinks received his pharmacy and pharmacology training with honors at Leiden University in the Netherlands and the University of Toronto, Canada. He received specialty training in clinical pharmacy (PharmD) and clinical pharmacology (PhD) at The Hague Hospitals Central Pharmacy and Leiden University. Dr. Vinks is board certified in Clinical Pharmacology and Toxicology. Before joining the Division of Clinical Pharmacology at Cincinnati Children’s, he was Director of the centralized Clinical Pharmacology & Toxicology Laboratory serving all hospitals and nursing homes in the city of The Hague, the Netherlands.
His major research interests include pharmacokinetic-pharmacodynamic (PK/PD) modeling, pharmacogenetics (PG) and the application of genomic, population and simulation approaches (Pharmacometrics) to clinical trial design, Therapeutic Drug Monitoring (TDM) and individualized Bayesian dosing strategies. His current research includes the development of pharmacogenetic and biomarker assays for the prediction of therapeutic response and side effects of immunosuppressive drugs. Dr. Vinks has ongoing NIH funding to further advance PK/PD/PG modeling and simulation in pediatric patients with a focus in optimizing immunosuppressive and antimicrobial therapies. He is directing several clinical pharmacology cores for ongoing multi-center clinical studies evaluating target controlled therapies using population model-based approaches.
Dr. Vinks has received several distinctions for his research, including the Huizinga Award for Research in Hospital Pharmacy in the Netherlands. Dr. Vinks is president-elect (2009) of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT). He also serves on the Coordinating Committee on Scientific Sections (CCSS) of the American Society of Clinical Pharmacology and Therapeutics (ASCPT) and is a fellow of the American College of Clinical Pharmacology. He is on the Editorial Board of Antimicrobial Agents and Chemotherapy, Clinical Therapeutics, Therapeutic Drug Monitoring, Journal of Pediatric Pharmacology and Therapeutics, and the Journal of Clinical Medicine (Bulgaria).
Dr. Vinks is an internationally renowned speaker with more than 150 presentations at national and international meetings. He has authored over 70 peer-reviewed publications and 14 book chapters and reviews in the areas of PK/PD modeling, pharmacogenetics and TDM.
-------------------------------------------
Go to top |
|
| |
|
|
11th International Congress of
